The RLT Arms Race: What ASCO 2026 Means for Your Theranostics Program

That was the practical message from ASCO 2026. The field is moving earlier in prostate cancer, alpha emitters are becoming more credible, antibody-based platforms are creating a different toxicity conversation, and imaging is becoming more important upstream.

For anyone building, operating, referring into, or investing around a theranostics program, the question is no longer just:

"Do you offer Pluvicto?"

The real question is becoming:

"Which isotope, which scaffold, which line of therapy, which imaging strategy, and in what sequence?"

That shift matters. It changes referral patterns. It changes clinic workflow. It changes patient selection. It changes how practices think about PET capacity, nursing education, payer policy, trial participation, and long-term program strategy.

The short version

Three themes stood out:

1. RLT is moving earlier. PSMAddition showed a radiographic progression-free survival benefit when [177Lu]Lu-PSMA-617 was added to standard of care in metastatic hormone-sensitive prostate cancer, with a reported rPFS hazard ratio of 0.72 at median 23.6 months follow-up (ESMO Daily Reporter).

2. Alpha emitters are maturing. Ac-225-PSMA-617 showed activity across multiple mCRPC settings, including patients previously treated with Lu-177, with PSA50 rates reported at 58.8 percent, 100 percent, and 56.3 percent across the three AcTION cohorts (UroToday).

3. Antibody-based RLT deserves attention. ProstACT Global and CONVERGE-01 suggest that antibody scaffolds may create a meaningfully different salivary and renal toxicity profile than small-molecule PSMA agents (Telix, UroToday).

The operational takeaway is simple: theranostics programs need to prepare for more complexity, not less.

At a glance

RLT is moving upstream

The biggest strategic implication is that RLT is moving earlier in the disease course.

PSMAddition tested [177Lu]Lu-PSMA-617 added to standard of care in PSMA-positive metastatic hormone-sensitive prostate cancer. The reported rPFS hazard ratio was 0.72, and the benefit appeared consistent across disease volume and presentation timing in subgroup reporting (ESMO Daily Reporter, UroToday).

That has a practical consequence.

If RLT becomes part of earlier prostate cancer management, PSMA PET screening starts moving closer to metastatic diagnosis. Referral pathways need to tighten between urology, medical oncology, radiation oncology, nuclear medicine, radiology, and the infusion or therapy team.

For a community or independent program, this means the operational question is not just whether you can deliver a radiopharmaceutical. It is whether your program can identify the right patient earlier, coordinate the workup faster, and handle the payer and logistics burden before the patient is already many lines into therapy.

Alpha therapy is becoming real

Actinium-225 has moved beyond theoretical interest.

The AcTION Phase 1 study reported activity across cohorts, including a PSA50 rate of 56.3 percent in the prior Lu-177 cohort and 100 percent in the chemo and ARPI-naive cohort (UroToday). The study also reported no dose-limiting toxicities and established 10 MBq every 8 weeks for up to 6 cycles as the recommended Phase 2 dose (UroToday).

The Phase 3 AcTFirst study then becomes important because it is designed to answer where Ac-225-PSMA-617 belongs in taxane-naive mCRPC, including comparison against investigator's choice standard of care (UroToday).

For theranostics programs, the alpha question is not abstract anymore. It is becoming a sequencing question, a toxicity question, a capacity question, and eventually a formulary question.

The antibody platforms may change the toxicity discussion

Small-molecule PSMA RLT has a known issue: salivary gland and renal uptake.

That is why antibody-based RLT deserves close attention. ProstACT Global is evaluating Lu-177-rosopatamab tetraxetan, also known as TLX591, in mCRPC. Early safety and dosimetry reporting described low radiation exposure to salivary glands and kidneys, with 5.6 percent of patients requiring a red blood cell transfusion in the reported safety cohort (Telix, UroToday).

CONVERGE-01 extends the same basic idea into alpha therapy after prior Lu-177-PSMA-617. In the reported efficacy subset, PSA50 was 40 percent, and the report described no high-grade xerostomia or nephrotoxicity (UroToday).

The tradeoff is hematologic toxicity. That has to be watched carefully. But if antibody scaffolds can reduce salivary and renal burden while preserving meaningful activity, they may become a major part of the sequencing map.

Imaging is the upstream bottleneck

Theranostics programs are only as good as their imaging and patient selection.

AMPLIFY is testing 64Cu-SAR-bisPSMA, a copper-64 PSMA PET agent with a longer half-life than conventional 18F and 68Ga tracers. The agent is designed to support delayed imaging and potentially higher lesion detection through longer tumor retention and background clearance (Clarity Pharmaceuticals, UroToday).

PSMAtrack adds another piece. It found persistent PSMA-avid disease on F18-flotufolastat PET at 6 months in metastatic hormone-sensitive prostate cancer patients on systemic therapy, even among patients with undetectable PSA (CancerNetwork, UroToday).

That matters because the field is moving toward earlier intervention. If PSA misses residual disease that PSMA PET can still see, imaging will increasingly drive intensification, consolidation, and referral decisions.

The practical bottom line

Here is how I would summarize the post-ASCO 2026 landscape for a theranostics program:

• Plan for earlier referrals. If RLT keeps moving upstream, you need a process for metastatic hormone-sensitive prostate cancer, not just late-line mCRPC.
• Build an alpha strategy. Ac-225 programs are credible enough that every serious program should understand the pipeline and likely sequencing implications.
• Watch antibody-based platforms. They may matter most for patients where xerostomia, renal exposure, or cumulative toxicity become limiting.
• Treat imaging as infrastructure. PET access, interpretation, reporting, and referral timing are not side issues. They are the front door to the entire program.
• Prepare the business office. More options mean more payer policy variation, more prior authorization complexity, more inventory coordination, and more education for referring offices.

The good news is that this complexity is good for patients. More targets, isotopes, and scaffolds mean more shots on goal.

The challenge is operational. The centers that build a real theranostics operating layer now will be better positioned as the field accelerates.

Closing CTA

If you run, refer into, or are building a theranostics program, subscribe to Theranostics Weekly. Each issue will focus on the clinical, operational, and business questions that determine whether these therapies actually reach patients.